Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 5 years
- Director since
- 2023
5 years of board service in total across 2 boards, counting each seat separately. Longest: Nektar Therapeutics, 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Viridian Therapeutics Inc. June 20, 202599.9%
-
Nektar Therapeutics June 5, 202494.4%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 23, 2026 | Nektar Therapeutics | Grant or award | +2,000 | — | — |
| May 2, 2024 | BioMarin Pharmaceutical Inc. | Open-market sale | −5,000 | $82.91 | $414,550 |
| Apr 30, 2024 | BioMarin Pharmaceutical Inc. | Grant or award | +300 | $68.65 | $20,595 |
| Mar 15, 2024 | BioMarin Pharmaceutical Inc. | Shares withheld for tax | −22,580 | $83.87 | $1,893,785 |
| Mar 5, 2024 | BioMarin Pharmaceutical Inc. | Open-market sale | −4,000 | $87.07 | $348,280 |
| Feb 27, 2024 | BioMarin Pharmaceutical Inc. | Grant or award | +21,440 | — | — |
| Feb 27, 2024 | BioMarin Pharmaceutical Inc. | Grant or award | +9,338 | — | — |
| Feb 27, 2024 | BioMarin Pharmaceutical Inc. | Grant or award | +6,465 | — | — |
| Sep 18, 2023 | Nektar Therapeutics | Open-market sale | −4,359 | $0.69 | $3,008 |
| Aug 16, 2023 | BioMarin Pharmaceutical Inc. | Open-market sale | −5,000 | $90.00 | $450,000 |
| Apr 28, 2023 | BioMarin Pharmaceutical Inc. | Grant or award | +318 | $66.88 | $21,268 |
Questions about Jeffrey Robert Ajer
What boards is Jeffrey Robert Ajer on?
Jeffrey Robert Ajer sits on the boards of Nektar Therapeutics and Viridian Therapeutics Inc.
How long has Jeffrey Robert Ajer served on boards?
Our records show at least 5 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.